ULK1/2 Inhibitors that Degrade ATG13 Effectively Target KRAS-Mutant CancersPatrick M. Hagan(Center for Cancer Research), Nicholas D. P. Cosford(Discovery Institute)bioRxiv (Cold Spring Harbor Laboratory)October 15, 202510.1101/2025.10.14.682402Cited by 0SaveCiteExport RISWatch citationsRelated PapersSynthesis and Characterization of ULK1/2 Kinase Inhibitors that Inhibit Autophagy and Upregulate Expression of Major Histocompatibility Complex I for the Treatment of Non-Small Cell Lung Cancer|bioRxiv (Cold Spring Harbor Laboratory)|2025|1